Vanda Pharmaceuticals Inc [NASDAQ: VNDA] gained 8.33% or 0.37 points to close at $4.81 with a heavy trading volume of 5541918 shares.
The daily chart for VNDA points out that the company has recorded 18.47% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 552.92K shares, VNDA reached to a volume of 5541918 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Vanda Pharmaceuticals Inc [VNDA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VNDA shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VNDA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Vanda Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 11, 2024. While these analysts kept the previous recommendation, Jefferies dropped their target price from $24 to $12. The new note on the price target was released on February 25, 2022, representing the official price target for Vanda Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $22, while BofA Securities analysts kept a Buy rating on VNDA stock.
The Average True Range (ATR) for Vanda Pharmaceuticals Inc is set at 0.22, with the Price to Sales ratio for VNDA stock in the period of the last 12 months amounting to 1.54. The Price to Book ratio for the last quarter was 0.52, with the Price to Cash per share for the same quarter was set at 6.65.
Trading performance analysis for VNDA stock
Vanda Pharmaceuticals Inc [VNDA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.89. With this latest performance, VNDA shares dropped by -5.69% in over the last four-week period, additionally plugging by 18.47% over the last 6 months – not to mention a rise of 10.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VNDA stock in for the last two-week period is set at 52.21, with the RSI for the last a single of trading hit 59.48, and the three-weeks RSI is set at 48.57 for Vanda Pharmaceuticals Inc [VNDA]. The present Moving Average for the last 50 days of trading for this stock 4.98, while it was recorded at 4.52 for the last single week of trading, and 4.83 for the last 200 days.
Vanda Pharmaceuticals Inc [VNDA]: A deeper dive into fundamental analysis
Vanda Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.67 and a Current Ratio set at 4.68.
Vanda Pharmaceuticals Inc [VNDA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Vanda Pharmaceuticals Inc posted 0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.16. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VNDA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vanda Pharmaceuticals Inc go to 36.10%.
An analysis of Institutional ownership at Vanda Pharmaceuticals Inc [VNDA]
There are presently around $77.05%, or 79.56%% of VNDA stock, in the hands of institutional investors. The top three institutional holders of VNDA stocks are: BLACKROCK INC. with ownership of 8.14 million shares, which is approximately 14.0895%. RENAISSANCE TECHNOLOGIES LLC, holding 4.11 million shares of the stock with an approximate value of $$23.24 million in VNDA stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $$19.39 million in VNDA stock with ownership which is approximately 5.9412%.
